Floatz logo

ATORVASTATIN

Abdominal Obesity-Metabolic Syndrome

Seoul National University HospitalSmall moleculePhase 4 / ApprovedDormant
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
75/ 100
Competitive Position
73/ 100

Competitive context

42 Active assets in the Abdominal Obesity-Metabolic Syndrome cohort.

Asset / SponsorPhaseRating
Topiramate
All India Institute of Medical Sciences, Bhubaneswar
Phase 4BBB
Pioglitazone
Philip Kern
Phase 4BBB
Rosuvastatin
Hamdard University
Phase 4BBB
SIMVASTATIN
Jaime Daniel Mondragon
Phase 4BBB
OLMESARTAN MEDOXOMIL
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Phase 4BBB

View all 50 →

Same molecule, other indications

ATORVASTATIN is also rated in:

inherited lipid metabolism disorderActive
A
Indicative · Phase 4
83 / 100
View asset →
hyperlipidemiaDormant
BBB
Indicative · Phase 4
79 / 100
View asset →
cardiovascular disorderActive
BBB
Indicative · Phase 4
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →